As of 2025-09-18, the Relative Valuation of Alnylam Pharmaceuticals Inc (ALNY) is (30.49) USD. This relative valuation is based on P/E multiples. With the latest stock price at 451.73 USD, the upside of Alnylam Pharmaceuticals Inc based on Relative Valuation is -106.7%.
The range of the Relative Valuation is (34.32) - (35.78) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 5.3x - 14.7x | 10.0x |
| Forward P/E multiples | 14.1x - 16.0x | 15.0x |
| Fair Price | (34.32) - (35.78) | (30.49) |
| Upside | -107.6% - -107.9% | -106.7% |
| Date | P/E |
| 2025-09-16 | -189.47 |
| 2025-09-15 | -189.43 |
| 2025-09-12 | -191.39 |
| 2025-09-11 | -192.49 |
| 2025-09-10 | -192.79 |
| 2025-09-09 | -198.06 |
| 2025-09-08 | -186.92 |
| 2025-09-05 | -185.68 |
| 2025-09-04 | -186.31 |
| 2025-09-03 | -183.80 |
| 2025-09-02 | -183.63 |
| 2025-08-29 | -183.42 |
| 2025-08-28 | -185.81 |
| 2025-08-27 | -186.57 |
| 2025-08-26 | -185.35 |
| 2025-08-25 | -182.24 |
| 2025-08-22 | -186.66 |
| 2025-08-21 | -192.07 |
| 2025-08-20 | -188.27 |
| 2025-08-19 | -188.26 |
| 2025-08-18 | -187.68 |
| 2025-08-15 | -184.41 |
| 2025-08-14 | -181.87 |
| 2025-08-13 | -177.68 |
| 2025-08-12 | -176.61 |
| 2025-08-11 | -178.70 |
| 2025-08-08 | -180.31 |
| 2025-08-07 | -178.74 |
| 2025-08-06 | -175.88 |
| 2025-08-05 | -172.09 |
| 2025-08-04 | -172.35 |
| 2025-08-01 | -165.06 |
| 2025-07-31 | -161.13 |
| 2025-07-30 | -139.59 |
| 2025-07-29 | -135.79 |
| 2025-07-28 | -133.42 |
| 2025-07-25 | -135.07 |
| 2025-07-24 | -134.74 |
| 2025-07-23 | -133.77 |
| 2025-07-22 | -133.62 |
| 2025-07-21 | -131.67 |
| 2025-07-18 | -131.67 |
| 2025-07-17 | -133.38 |
| 2025-07-16 | -132.61 |
| 2025-07-15 | -127.81 |
| 2025-07-14 | -129.71 |
| 2025-07-11 | -129.38 |
| 2025-07-10 | -132.54 |
| 2025-07-09 | -131.81 |
| 2025-07-08 | -130.43 |